Tus Neeg Mob Australian Ua Tau Zoo Kawg Nkaus Thaum Ntxov Nrog BIOOCUS Medical Group's Dual CD19/CD20 CAR-T Therapy Rau Cov Neeg Mob DLBCL Rov Qab Los
Rodney Charles Monger, ib tug txiv neej hnub nyoog 68 xyoo los ntawm Australia, tau kuaj pom tias muaj kab mob loj heev diffuse B-Cell Lymphoma (DLBCL) peb xyoos dhau los. Nrhiav kev kho mob siab heev, nws tig mus rau BIOOCUS Medical Group thaum Lub Yim Hli 2025. Kev kuaj mob qog nqaij hlav ntawm lub caj dab tau lees paub tias muaj kab mob B-cell lymphoma uas muaj keeb kwm los ntawm lub hauv paus chiv keeb. Immunohistochemistry zoo heev rau CD20, CD19, thiab CD10, nrog rau kev qhia tawm siab ntawm Bcl-6, Bcl-2 (70%+), thiab c-MYC (60%+). Kev kuaj noob caj noob ces tau qhia txog BCL2 rearrangement los ntawm FISH thiab kev hloov pauv hauv EZH2, KMT2D, TNFRSF14, NRAS, thiab TPMT genes—cov cim qhia meej ntawm qhov muaj kev phom sij, muaj kev pheej hmoo siab.
Tom qab tau txais pola ua ke nrog BTK inhibitor thiab lenalidomide, ua raws li FC lymphodepletion chemotherapy, Mr. Monger tus kab mob tseem tsis tau kho. Pab neeg ntawm BIOOCUS Medical Group tau pom zoo lawv txoj kev kho mob CD19/CD20 CAR-T cell dual-targeting.
Thaum lub Cuaj Hlis 8, 2025, Mr. Monger tau txais cov qe ntshav dawb CD19/CD20 CAR-T uas yog nws tus kheej. Qhov zoo kawg nkaus, nws tsis muaj mob cytokine release syndrome (CRS) thiab tsis muaj mob immune effector cell-associated neurotoxicity syndrome (ICANS), ua rau nws zoo siab tom qab txhaj tshuaj uas ua rau nws ruaj khov thiab zoo siab txij li hnub thawj.
Kev soj ntsuam cov ntshav ntawm cov hlab ntsha tau pom tias cov hlwb CAR-T nthuav dav zoo kawg nkaus, ua pov thawj tias lawv tau cog thiab loj hlob zoo heev. Nyob rau hnub 4 tom qab txhaj tshuaj, cov hlwb CAR19+ yog 0.50% ntawm cov hlwb CD3+ T (tus nqi tag nrho yog 6.04 × 10⁷/L) thiab cov hlwb CAR20+ yog 0.41% (4.96 × 10⁷/L). Txog hnub 7, CAR19+ nce mus txog 1.68% (1.40 × 10⁷/L) thiab CAR20+ mus txog 1.63% (1.36 × 10⁷/L). Nyob rau hnub 10, CAR19+ mus txog 31.43% ntawm cov hlwb CD3+ T (tus nqi tag nrho yog 3.13 × 10⁸/L) thiab CAR20+ mus txog 32.74% (tus nqi tag nrho yog 3.26 × 10⁸/L). Kev ntsuas cov kua dej ntws (flow cytometry) kuj qhia tau tias muaj kev faib tawm sib npaug thoob plaws CD4+ thiab CD8+ subsets nrog kev qhia tawm CAR ob npaug, qhia txog kev kho mob lub peev xwm los txhawb kev nyob ruaj khov thiab kev loj hlob hauv lub cev.
Nyob rau hnub tim 10 tom qab kuaj mob tas los no, Mr. Monger tseem ua tau zoo hauv kev kho mob. Nws noj tshuaj uas tsim tshwj xeeb rau nws noj xws li acyclovir, compound sulfamethoxazole, orelabrutinib, lenalidomide, thiab cov tshuaj pab txhawb nqa, nrog rau kev saib xyuas cov ntshav, kev ua haujlwm ntawm lub siab thiab lub raum, thiab cov cim qhia txog kev o.
Pawg neeg BIOOCUS Medical Group tau muab kev txhawb nqa dav dav, tsom mus rau tus neeg mob thoob plaws, suav nrog chaw nyob zoo, zaub mov muaj txiaj ntsig zoo, kev pab thauj mus los, thiab kev sab laj txog kev puas siab puas ntsws rau Mr. Monger thiab nws tsev neeg. Txoj kev kho mob no ua rau nws tsom mus rau kev kho mob tag nrho.
Cov ntaub ntawv ntawm Mr. Monger qhia txog lub peev xwm hloov pauv ntawm BIOOCUS Medical Group txoj kev kho mob CD19/CD20 CAR-T ob zaug rau cov neeg mob uas rov qab mob/tsis kho tau DLBCL. Kev nthuav dav sai thiab muaj zog ntawm CAR-T hlwb yam tsis muaj kev lom loj heev qhia txog cov khoom muaj kev nyab xeeb zoo thiab kev ua haujlwm tiv thaiv qog nqaij hlav - txawm tias hauv tus neeg mob laus uas muaj cov yam ntxwv molecular muaj kev pheej hmoo siab.